Registered title, quoted from ClinicalTrials.gov
A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07900516, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Histopathologically confirmed HR+/HER2- breast cancer: estrogen receptor (ER)-positive (>10%), regardless of progesterone receptor (PR) expression level; HER2-negative invasive breast carcinoma as per the 2018 ASCO-CAP HER2-negative interpretation guidelines, confirmed by the pathology laboratory as immunohistochemistry (IHC) 0, 1+, or 2+ with negative in situ hybridization (ISH) (HER2/CEP17 ratio <2.0).
Inclusion criterion 3
Initially diagnosed with stage II-III breast cancer according to the AJCC 8th edition staging system.
Inclusion criterion 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Inclusion criterion 5
At least one measurable lesion according to RECIST version 1.1.
Inclusion criterion 7
Other malignancies within the past 5 years, except for cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
Exclusion criterion 5
History of immunodeficiency, including positive HIV test, positive HCV antibodies, active hepatitis B virus infection (HBsAg positive with detectable HBV DNA), or other acquired/congenital immunodeficiency diseases, or history of organ transplantation.
Exclusion criterion 9
Pregnant or breastfeeding women, or women of childbearing potential with a positive baseline pregnancy test.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07900516, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Initially diagnosed with stage II-III breast cancer according to the AJCC 8th edition staging system.
- Premenopausal or perimenopausal patients (who must receive ovarian function suppression [OFS], including bilateral oophorectomy or GnRHa [GnRH agonists]), or postmenopausal patients.
- Histopathologically confirmed HR+/HER2- breast cancer: estrogen receptor (ER)-positive (>10%), regardless of progesterone receptor (PR) expression level; HER2-negative invasive breast carcinoma as per the 2018 ASCO-CAP HER2-negative interpretation guidelines, confirmed by the pathology laboratory as immunohistochemistry (IHC) 0, 1+, or 2+ with negative in situ hybridization (ISH) (HER2/CEP17 ratio <2.0).
- Female patients aged 18-75 years (inclusive).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥12 weeks.
- At least one measurable lesion according to RECIST version 1.1.
- Adequate organ function as defined by:
Hematology: absolute neutrophil count (ANC) >=1.5×10⁹/L; platelet count (PLT) ≥100×10⁹/L; hemoglobin (Hb) >=90 g/L.
Blood biochemistry: total bilirubin (TBIL) =<1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<3×ULN; blood urea nitrogen (BUN) and creatinine (Cr) =<1.5×ULN, and creatinine clearance >=50 mL/min.
9.12-lead electrocardiogram (ECG) with QTc interval ≤480 ms. 10.Willing to voluntarily participate, provide written informed consent, and comply with study visits and follow up.
Exclusion Criteria:
- Prior receipt of any form of anti tumor therapy (including chemotherapy, radiotherapy, molecularly targeted therapy, endocrine therapy, etc.).
- Concurrent use of other anti tumor drugs.
- Stage IV breast cancer.
- Breast cancer not confirmed by histopathology.
- Other malignancies within the past 5 years, except for cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
- Severe dysfunction of vital organs such as heart, liver, or kidneys.
- Inability to swallow, chronic diarrhea, or intestinal obstruction, or any condition that may affect oral drug absorption.
- Participation in another drug clinical trial within 4 weeks prior to enrollment.
- History of immunodeficiency, including positive HIV test, positive HCV antibodies, active hepatitis B virus infection (HBsAg positive with detectable HBV DNA), or other acquired/congenital immunodeficiency diseases, or history of organ transplantation.
- Known hypersensitivity to any component of the study drugs.
- Any cardiac disease, including: arrhythmia requiring medication or clinically significant; myocardial infarction; heart failure; or any other cardiac condition deemed by the investigator as unsuitable for participation.
- Pregnant or breastfeeding women, or women of childbearing potential with a positive baseline pregnancy test.
- Concurrent medical conditions that, in the investigator's judgment, may compromise patient safety or interfere with study completion (including but not limited to severe hypertension not controlled by medication, severe diabetes, active infections, etc.).
Quoted from ClinicalTrials.gov, NCT07900516, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07900516, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.